Synthetic lethality is a lethal phenomenon in which the occurrence of a single genetic event is tolerable for cell survival, whereas the co-occurrence of multiple genetic events results in cell death. The main obstacle for synthetic lethality lies in the tumor biology heterogeneity and complexity, the inadequate understanding of synthetic lethal interactions, drug resistance, and the challenges regarding screening and clinical translation. Recently, DNA damage response inhibitors are being tested in various trials with promising results. This review will describe the current challenges, development, and opportunities for synthetic lethality in cancer therapy. The characterization of potential synthetic lethal interactions and novel technologies to develop a more effective targeted drug for cancer patients will be explored. Furthermore, this review will discuss the clinical development and drug resistance mechanisms of synthetic lethality in cancer therapy. The ultimate goal of this review is to guide clinicians at selecting patients that will receive the maximum benefits of DNA damage response inhibitors for cancer therapy.

Recently, genetically targeted cancer therapies have been a topic of great interest. Synthetic lethality provides a new approach for the treatment of mutated genes that were previously considered unable to be targeted in traditional genotype-targeted treatments. The increasing researches and applications in the clinical setting made synthetic lethality a promising anticancer treatment option. However, the current understandings on different conditions of synthetic lethality have not been systematically assessed and the application of synthetic lethality in clinical practice still faces many challenges. Here, we propose a novel and systematic classification of synthetic lethality divided into gene level, pathway level, organelle level, and conditional synthetic lethality, according to the degree of specificity into its biological mechanism. Multiple preclinical findings of synthetic lethality in recent years will be reviewed and classified under these different categories. Moreover, synthetic lethality targeted drugs in clinical practice will be briefly discussed. Finally, we will explore the essential implications of this classification as well as its prospects in eliminating existing challenges and the future directions of synthetic lethality.

As ite-selective electrochemical … …C of arenes with CO 2 is reported by Youai Qiu and co-workers Research Article (e202214710). Ad irect metal-free,b ase-free,a nd site-selective electrochemical CÀHc arboxylation of arenes by reductive activation using CO 2 as an economic and abundant carboxyl source was developed. Ther obust nature of this strategy is reflected in abroad scope of substrates,excellent atom economy,and unique selectivity.

Herein, we report ag eneral iminium ion-based catalytic method for the enantioselective conjugate addition of carbon-centered radicals to aliphatic and aromatic enals.T he process uses an organic photoredox catalyst, whicha bsorbs blue light to generate radicals from stable precursors,i n combination with ac hiral amine catalyst, which secures ac onsistently high level of stereoselectivity.T he generality of this catalytic platform is demonstrated by the stereoselective interception of aw ide variety of radicals,i ncluding nonstabilized primary ones whichare generally difficult to engage in asymmetric processes.T he system also served to develop organocatalytic cascade reactions that combine an iminiumion-based radical trap with an enamine-mediated step,affording stereochemically dense chiral products in one-step.

Herein, an electroreductive carboxylation of organic carbon-halogen bonds (X = Br and Cl) promoted by catalytic amounts of naphthalene as an organic mediator is reported. This transformation proceeds smoothly under mild conditions with a broad substrate scope of 59 examples, affording the valuable and versatile carboxylic acids in moderate to excellent yields without the need of costly transition metal, wasted stoichiometric metal reductants, or sacrificial anodes. Further late-stage carboxylations of natural product and drug derivatives demonstrate its synthetic utility. Mechanistic studies confirmed the activation of carbonhalogen bonds via single-electron transfer and the key role of naphthalene in this reaction.